文献速递鼻科

围手术期短程度普利尤单抗辅助治疗联合内镜鼻窦手术治疗复发性慢性鼻窦炎伴鼻息肉

Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-10-23

这项前瞻性、安慰剂对照、双盲试验纳入30例复发性慢性鼻窦炎伴鼻息肉成人患者,在内镜鼻窦手术前后给予14周度普利尤单抗或安慰剂,随访至术后52周。两组鼻通畅感、嗅觉和生活质量均改善,度普利尤单抗组术后12个月嗅觉丧失比例为33.3%,安慰剂组为50.0%,且度普利尤单抗组血清IgE持续下降。

要点

  • 围手术期短程度普利尤单抗辅助治疗与更长期的嗅觉获益相关。
  • 术后12个月嗅觉丧失比例:度普利尤单抗组33.3% vs 安慰剂组50.0%。
  • 度普利尤单抗组血清IgE持续下降,安慰剂组未见此现象。

核心结论

  • 围手术期短程度普利尤单抗辅助治疗与更长期的嗅觉结局改善及血清IgE持续降低相关。

研究设计与样本

  • 前瞻性、安慰剂对照、双盲试验,纳入30例复发性慢性鼻窦炎伴鼻息肉成人患者。
  • 患者接受内镜鼻窦手术联合或不联合14周围手术期度普利尤单抗,于术前4周(两次注射)开始给药。
  • 随访至术后52周,监测鼻通畅感、嗅觉、生活质量及不良事件的主观和客观指标,并进行微生物培养。

主要发现

  • 两组内镜鼻窦手术均安全改善鼻通畅感、嗅觉和生活质量的主观和客观指标。
  • 度普利尤单抗组嗅觉保持更久,术后12个月嗅觉丧失比例为33.3%,安慰剂组为50.0%。
  • 度普利尤单抗组血清IgE持续下降,安慰剂组未见此现象。
  • 未观察到异常安全信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with a high rate of disease recurrence following endoscopic sinus surgery (ESS). Type 2 disease is associated with a higher incidence of recurrence and is believed to impact disease resolution via interference with epithelial healing and pathogen immunity. We wished to verify if perioperative control of Type 2 inflammation with an anti-IL4/IL13 targeting monoclonal antibody and during the resolution period following surgery leads to better control of the disease long term. METHODS: In this prospective, placebo-controlled, double-blinded trial. Thirty adult subjects with recurrent CRSwNP underwent ESS plus or minus 14 weeks of perioperative dupilumab, initiated 4 weeks (two injections) pre-ESS. Subjective and objective parameters of nasal patency, olfaction, quality of life (QoL), and adverse events were monitored up to 52 weeks post-ESS. Microbiological culture was performed to characterize pathogens colonization under both conditions. RESULTS: ESS safely improved subjective and objective measures of nasal patency, olfaction, and QoL in both groups. Olfaction was conserved longer in the dupilumab-treated group, with 33.3% of subjects presenting anosmia at 12 months after ESS in the dupilumab group compared to 50.0% with placebo. This was associated with persistent decreases in serum IgE, which were not seen with placebo treatment. No unusual safety signals were observed. CONCLUSION: Short-course adjuvant perioperative treatment with dupilumab is associated with improved long-term olfactory outcomes and persistent lowering of serum IgE.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Pelletier A, Endam LM, Gonzalez E, et al. Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. Int Forum Allergy Rhinol. 2024. PMID: 39444257. doi:10.1002/alr.23471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。